New eczema study with Airsonett AIR4 published
Promising results from an independent prospective pilot study lead by Dr. Claudia Gore, Imperial College, London has recently been published. The study showed that treatment with Temperature controlled Laminar Airflow (TLA; Airsonett AIR4) can lead to a significant clinical improvement in children and adolescents with severe allergic eczema, with accompanying reduction in medication usage.
Allergic eczema (also called atopic dermatitis) is a chronic inflammatory skin disease affecting up to 20% of children. Severe allergic eczema inflicts a substantial burden on patients and their families. Children and parents are burdened with time-consuming topical treatment regimens. In addition, many families must deal with a significant loss of sleep related to night-time itching and scratching.
The TLA device has previously been shown to significantly reduce the number of inhaled allergens and other potential trigger factors in the breathing zone over night, leading to decreased symptoms and improved quality of life in patients suffering from allergic asthma.
The current study was designed to evaluate the effectiveness of overnight treatment with the TLA device (Airsonett AIR4) in children and adolescents with severe allergic eczema over a 12-month period.
Fifteen children (2-16 years) with longstanding severe allergic eczema (atopic dermatitis) were followed during a 12-month treatment period. The study results included significant improvements in SCOR ring of Atopic Dermatitis (SCORAD) index, Investigator Global Assessment (IGA) and Family
Dermatology Quality of Life index (FDQLI) after 12 months treatment. Importantly, the clinical improvement was accompanied by a reduction in the use of potent topical corticosteroids.
“We have many reports from patients with severe allergic eczema whose symptoms have improved substantially with AIR4 and it is very positive that this study supports those observations.” says JonasBåghammar, VP Business Development at Airsonett AB.